Promontory’s prostate cancer trial reaches patient enrolment milestone

Promontory’s prostate cancer trial reaches patient enrolment milestone

Source: 
Clinical Trials Arena
snippet: 

Promontory Therapeutics has announced the completion of subject enrolment for its Phase II clinical trial of PT-112, a lead therapeutic candidate for metastatic castration-resistant prostate cancer (mCRPC).